TrakGene vs Phenotips: an honest comparison

This page is a head-to-head comparison of TrakGene and Phenotips. Teams searching "trakgene vs phenotips" typically want a plain-English summary of which is the better fit for their service. That is what this page provides. Evagene is briefly introduced at the end as a third option for readers whose requirements emphasise modern AI, REST API, and agentic integration — but this article is genuinely about TrakGene and Phenotips first. All product claims are drawn from each vendor's public website and documentation as of April 2026.

Short version. Choose TrakGene if your institution is FHIR-first, you want a clinician-built platform with an AI copilot and a broad integrated service set, and you value customer references such as NIH, NHS, and Geisinger. Choose Phenotips if your service is phenotype-first rare disease diagnostics with HPO at the centre, you need a global genomic health record with advertised GDPR/DSPT/HIPAA/CE+ certifications, and LGBTQIA+-inclusive design is a priority.

How TrakGene and Phenotips position themselves

TrakGene presents itself as a clinician-built clinical genetics platform. The origin story matters: a product built by clinicians for clinicians usually shows it in the defaults, and TrakGene's are oriented towards real clinical workflow. Its public material highlights 50+ integrated clinical services, 800+ users, native HL7 FHIR support, HPO phenotyping, risk modelling spanning CanRisk (BOADICEA), GAIL, and ClinVar variant context, and an AI copilot for clinical workflow. Its customer references include the NIH, the NHS, and Geisinger, which signal credible large-institution deployment. TrakGene supports both cloud and on-prem deployment. There is no free tier advertised.

Phenotips positions itself as "the complete Genomic Health Record" — an EHR-integrated solution for collaborative genomic medicine. Its emphasis is HPO-driven phenotype capture paired with automated gene and disease suggestion, targeted at rare disease diagnostics. It claims 100,000+ patient records, 500+ specialists, and deployment across 60+ countries. It advertises certifications across GDPR, DSPT, HIPAA, and CE+, and its design is LGBTQIA+-inclusive. Ownership sits with Gene42 / Think Research. Phenotips publishes a Research Team plan at $399/month for 5 users plus $25/user additional; clinic and hospital tiers are priced on application.

Both products are modern and credible. They are not interchangeable. TrakGene's centre of gravity is "integrated clinical genetics platform for institutions using FHIR as the connecting layer". Phenotips's centre of gravity is "modern genomic health record with HPO phenotype capture as the diagnostic engine".

Feature comparison

The matrix below compares features each vendor publishes. A tick means the capability is publicly advertised; a dash means it is not publicly listed. Evagene appears as a third column for readers considering a modern alternative.

Matrix compiled from publicly available product pages and documentation as of April 2026. "—" indicates the capability is not publicly advertised and does not necessarily mean it is absent.

FHIR-first vs HPO-first

The clearest axis of difference is integration philosophy. TrakGene's native HL7 FHIR support positions the product to fit into a FHIR-centric institutional IT estate — and for large hospitals and systems that have standardised on FHIR as their interoperability layer, that alignment is a significant advantage. Patient records, observations, and conditions flow between TrakGene and the EHR through FHIR resources, which keeps interfaces maintainable over time and reduces the bespoke glue that tends to accumulate between genetics platforms and hospital IT.

Phenotips emphasises HPO as its phenotype vocabulary. HPO is itself a gold-standard ontology for rare disease phenotyping; its role in Phenotips is not as an interoperability layer but as the diagnostic scaffolding that makes phenotype-to-gene suggestion possible. The two products are not competing on the same axis here: TrakGene's FHIR is about moving data in and out of other systems; Phenotips's HPO is about what the system knows and how it reasons.

A FHIR-heavy hospital IT team will nod when TrakGene is mentioned. A rare disease diagnostic service will nod when Phenotips is mentioned. Both reactions are correct.

Risk models and clinical analytics

TrakGene's public material advertises a broad risk-model stack: CanRisk (incorporating BOADICEA), GAIL, and ClinVar variant context as part of a genetics-wide workflow. For services whose cancer risk decisions involve comparing results from multiple models — common in NCCN-aligned cancer genetics clinics — TrakGene gives you the models you expect to see.

Phenotips advertises simultaneous execution of multiple cancer risk models but does not publicly enumerate the exact set. Its intelligence is stronger on phenotype-to-gene suggestion than on publishing a canonical list of risk models.

Neither product is wrong to frame their analytics as they do. If cancer risk is the critical path for your service and you want specific models named and published, TrakGene's disclosure is more complete. If phenotype-driven rare disease diagnostics is the critical path, Phenotips's HPO-native approach is more aligned.

AI, deployment, and institutional fit

TrakGene advertises an AI copilot — an LLM-era assistant built into the clinical workflow. Specifics of what it does and which models back it should be confirmed with the vendor, but the mere fact of its public advertisement signals that TrakGene is moving into AI-augmented clinical workflow. Phenotips's intelligence is its phenotype-to-gene pipeline; public materials do not advertise an LLM-based clinical assistant at the same level.

On deployment, TrakGene supports both cloud and on-premise, which matters for institutions with strong data localisation or network egress policies. Phenotips emphasises cloud deployment.

On institutional fit, TrakGene's NIH/NHS/Geisinger references are exactly the customers a government health system or large US integrated delivery network might ask about. Phenotips's 60+ country footprint is the reference pattern for a globally distributed clinical network, and its advertised GDPR/DSPT/HIPAA/CE+ certification passes institutional procurement reviews in many jurisdictions.

When to choose TrakGene

• Your institution has standardised on HL7 FHIR and wants a genetics platform that speaks FHIR natively.
• You value a clinician-built product with a customer base including NIH, NHS, and Geisinger.
• Your workflow needs a published risk-model stack (CanRisk/BOADICEA, GAIL) and ClinVar variant context.
• You need on-premise deployment, or the option of it, alongside cloud.
• You want an AI copilot integrated into the clinical workflow today.

When to choose Phenotips

• Your service is phenotype-driven rare disease diagnostics and HPO capture is central.
• You need a broad genomic health record platform, not just a pedigree or risk tool.
• Global deployment matters and you want advertised GDPR/DSPT/HIPAA/CE+ certifications.
• LGBTQIA+-inclusive design is a procurement criterion.
• You are comfortable with partial public pricing ($399/month for a research tier) and an enterprise quote motion for clinic tiers.

A third option to consider: Evagene

TrakGene and Phenotips are both strong enterprise-class platforms. For services whose priorities include modern AI integration using their own LLM keys, a public REST API for custom integration, and an MCP server for AI agents, Evagene is worth evaluating alongside them.

Evagene is a browser-based clinical pedigree management platform with gesture drawing, a 200+ disease catalogue coded to ICD-10 and OMIM, integrated BayesMendel cancer risk models (BRCAPRO, MMRpro, PancPRO), Mendelian inheritance analysis for AD/AR/XR patterns, karyogram viewing, and consanguinity detection via Wright's coefficient.

Its AI layer is bring-your-own-key: the service provides its own Anthropic Claude or OpenAI GPT credentials, encrypted at rest with Fernet, and clinical text flows directly to the model provider the service has already risk-assessed. Analysis Templates codify house style of report writing. The MCP server exposes 11 pedigree tools to Claude Desktop, Claude Code, and other MCP-compatible agents.

The integration surface comprises a scoped, rate-limited REST API with keys in the format evg_ followed by 43 characters (SHA-256 hashed at rest), HMAC-SHA256-signed webhooks, and an embeddable pedigree viewer (iframe / SVG / JavaScript). Imports cover GEDCOM 5.5.1, JSON, 23andMe, XEG, and pedigree image OCR. Exports cover PNG, SVG, and PDF across 4 report types.

Evagene is in Alpha and free via waiting list at evagene.com. It does not replace TrakGene's FHIR-first integration or Phenotips's HPO-first rare disease depth for institutions that need those today. It offers a credible modern alternative for services whose priorities are AI and programmatic access.

Frequently asked questions

Related reading

• Phenotips vs Evagene
• TrakGene vs Evagene
• Phenotips vs Progeny
• FamGenix vs Phenotips
• Pedigree drawing software: a practical guide
• All Evagene comparisons